Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 89Lymphoma, Non-Hodgkin 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 81Leukemia, Lymphocytic, Chronic, B-Cell 65Lymphoma, Large B-Cell, Diffuse 54Lymphoma, Follicular 50Burkitt Lymphoma 40Hodgkin Disease 39Recurrence 37Multiple Myeloma 33Leukemia, Myeloid, Acute 32Leukemia 32Lymphoma, Mantle-Cell 31Lymphoma, B-Cell 31Neoplasms 23Myelodysplastic Syndromes 22Hematologic Neoplasms 21Lymphoma, B-Cell, Marginal Zone 17Waldenstrom Macroglobulinemia 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Leukemia, B-Cell 14Sarcoma 13Lymphoma, T-Cell 11Lymphoma, Large-Cell, Anaplastic 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, T-Cell, Peripheral 10Glioma 10Osteosarcoma 9Neuroblastoma 9Mycosis Fungoides 9

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Attributes × Lymphoid × 30 days × Clear all
NCT05826535 2026-05-28

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma, Inc.

Phase 1/2 Recruiting
270 enrolled
Lymphoid

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡